NASDAQ:IRON 17 October 2025 - 1 January 2026

NEW YORK, January 1, 2026, 10:07 ET — Market closed Disc Medicine, Inc. shares rose 3.3% to $79.41 in the last U.S. trading session of 2025, before Wall Street shut on Thursday for the New Year’s Day holiday.

Disc Medicine, Inc. stock sank sharply on Friday, Dec. 19, 2025, with IRON down about 10% in late-morning trading and swinging through a wide intraday range that, at one point, dipped into the low $70s before rebounding toward the low $80s. MarketScreener The timing matters: the selloff arrives just weeks before investors expect clarity on Disc’s most important near-term catalyst—an FDA decision on bitopertin for erythropoietic protoporphyria—and amid a burst of insider-trading disclosures and Form 144 filings that can spook momentum-driven biotech traders even when sales are planned. MarketBeat+1

Disc Medicine’s stock price spiked dramatically in mid-October 2025 after news of the FDA voucher, vaulting from the mid-$70s to the low-$90s in a single daygurufocus.com. On Friday, IRON opened around $85 and surged to an intraday high of $92.50 before closing at $93.00, marking a ~25% jump on the daystockanalysis.com. This leap capped a steady uptrend over the past month – the shares were trading near $60 in early September and gradually climbed into the $70s as anticipation built around bitopertin’s NDA filing and reviewstockanalysis.comstockanalysis.com. The FDA’s award of a priority review voucher was the clear catalyst for the latest rally, as it significantly accelerates Disc’s timeline to a potential approval. The stock’s year-to-date performance now far outpaces broader biotech indices, reflecting how quickly sentiment can turn when a small biotech achieves a major regulatory win. Investor enthusiasm saw IRON hit all-time highs on this news. The ~$93 closing price on Oct. 17 is not only a 52-week high but also the stock’s highest level since Disc Medicine went public via merger in 2022. Trading volume spiked as well – over 760,000 shares changed hands on Oct. 17, roughly triple the typical daily volumestockanalysis.com – indicating intense interest from